| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | GSK-J4 | CTRPv2 | pan-cancer | AAC | -0.34 | 0.02 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | 0.11 | 0.02 |
| mRNA | betulinic acid | CTRPv2 | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.02 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.096 | 0.02 |
| mRNA | skepinone-L | CTRPv2 | pan-cancer | AAC | -0.15 | 0.02 |
| mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | 0.2 | 0.02 |
| mRNA | PF-573228 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.02 |
| mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | -0.083 | 0.02 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.02 |